Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers

Cornea

Volumn 29, Issue 7, 2010, Pages 751-757

  Shah, Vinit Mahendra ^a   Tandon, Radhika ^a   Satpathy, Gita ^a   Nayak, Niranjan ^a   Chawla, Bhavna ^a   Agarwal, Tushar ^a   Sharma, Namrata ^a   Titiyal, Jeewan S ^a   Vajpayee, Rasik B ^a,b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

corneal ulcers; fluoroquinolones; fortified antibiotics; gatifloxacin; moxifloxacin

Indexed keywords

ACETAZOLAMIDE; CEFAZOLIN; GATIFLOXACIN; HOMATROPINE METHYL BROMIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMOLOL; TOBRAMYCIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA OPACITY; CORNEA ULCER; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HEALING; HUMAN; INTRAOCULAR HYPERTENSION; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; BACTERIA; CORNEAL ULCER; DRUG COMBINATION; DRUG EFFECTS; EYE INFECTIONS, BACTERIAL; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA; CEFAZOLIN; CHILD; CORNEAL ULCER; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; TOBRAMYCIN; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 77954424192     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181ca2ba3     Document Type: Article

References (31)

1. O'Brien TP. Bacterial keratitis. In: Smolin G, Thoft RA, eds. The Cornea Scientific Foundations and Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:235-288.
2. Bennett HG, Hay J, Kirkness CM, et al. Antimicrobial management of presumed microbial keratitis: guidelines for treatment of central and peripheral ulcers. Br J Ophthalmol. 1998;82:137-145. (Pubitemid 28176987)
3. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. Ciprofloxacin 0.3% ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment Bacterial Keratitis Study Group. Arch Ophthal-mol. 1993;111:1210-1218.
4. Parks DJ, Abrams DA, Sarfarazi FA, et al. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol. 1993;115:471-477.
5. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995; 113:1257-1265.
6. Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol. 1979;24:97, 105-116.
7. Wilhelmus KR, Gilbert ML, Osato MS. Tobramycin in ophthalmology. Surv Ophthalmol. 1987;32:111-122.
8. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1966;103:1854-1862.
9. Gangopadhyay N, Daniell M, Weih L, et al. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol. 2000;84: 378-384. (Pubitemid 30255486)
10. Prajna NV, George C, Selvaraj S, et al. Bacteriologic and clinical efficacy of ofloxacin 3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. Cornea. 2001;20:175-178. (Pubitemid 32174088)
11. Maffett M, O'Day DM. Ciprofloxacin-resistant bacterial keratitis. Am J Ophthalmol. 1993;115:545-546.
12. Kunimoto DY, Sharma S, Garg P, et al. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999;106:80-85.
13. Goldstein MH, Kowalski RP, Gordon YJ. Emerging f1uoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106:1313-1318.
14. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004;49:S73-S78. (Pubitemid 38353038)
15. Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005;50:S16-S31.
16. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol. 2005;50:S32-S45. (Pubitemid 41657597)
17. Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and non-pediatric patients with bacterial conjunctivitis. Surv Ophthalmol. 2005;50:S55-S63.
18. Deramo VA, Lai JC, Fastenberg DM, et al. Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol. 2006;142:721-725.
19. Jensen H, Zerouala C, Carrier M, et al. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. J Ocul Pharmacol Ther. 2005;21:36-43. (Pubitemid 40280240)
20. Dajcs JJ, Thibodeaux BA, Marquart ME, et al. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother. 2004;48: 1948-1952. (Pubitemid 38691581)
21. Parmar P, Salman A, Kalavathy CM, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol. 2006;141:282-286. (Pubitemid 43188027)
22. Bauer ALS, Kirby LSMM, Sherris JC, et al. Antibiotic susceptibility\ testing by standardized disc method. Am J Clin Pathol. 1966;45: 493-496.
23. Schaefer F, Bruttin O, Zografos L, et al. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol. 2001;85:842-847. (Pubitemid 32662086)
24. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003;87:834-838. (Pubitemid 36765243)
25. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27:22-27.
26. Bharathi MJ, Ramakrishnan R, Vasu S, et al. Epidemiology of bacterial keratitis in a referral centre in south India. Indian J Med Microbiol. 2003; 114:1622-1629. (Pubitemid 37455990)
27. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, south India. Br J Ophthalmol. 1997;81:965-971. (Pubitemid 27493983)
28. Upadhyay MP, Karmacharya PC, Koirala S, et al. Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am J Ophthalmol. 1991;111:92-99.
29. Constantinou M, Daniell M, Snibson GR, et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology. 2007;114:1622-1629. (Pubitemid 47332654)
30. Jhanji V, Sharma N, Satpathy G, et al. Fourth generation fluoroquinolones resistant bacterial keratitis. J Cataract Refract Surg. 2007;33: 1488-1489.
31. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005;112:466-469. (Pubitemid 40312502)